Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

Dose-dependent Oxidative Damage of Molnupiravir (Antiviral Drug for Treatment of COVID-19) in Lung, Liver, Heart, and Kidney Tissues in Rats

Tanbek et al., Archives of Pharmacology and Therapeutics, doi:10.33696/Pharmacol.4.044
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Rat study showing dose-dependent oxidative damage with molnupiravir in lung, liver, heart, and kidney tissues. Authors found that molnupiravir decreased SOD activity and increased MDA, TOS, and OSI levels in multiple tissues, indicating oxidative stress and lipid peroxidation. ALT levels also increased in liver tissue at higher doses. The study suggests molnupiravir may cause tissue damage by disrupting oxidant/antioxidant balance in a dose-dependent manner. Lower doses, shorter treatment, or co-administration with antioxidants may reduce potential adverse effects.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-10. Multiple analyses have identified variants potentially created by molnupiravir11-15.
Tanbek et al., 4 Nov 2023, peer-reviewed, 2 authors. Contact: suleyman.sandal@inonu.edu.tr.
This PaperMolnupiravirAll
Dose-dependent Oxidative Damage of Molnupiravir (Antiviral Drug for Treatment of COVID-19) in Lung, Liver, Heart, and Kidney Tissues in Rats
Kevser Tanbek, Suleyman Sandal
did not respond to treatment and vaccines, which emerged in Wuhan, the capital of China's Hubei region, in December 2019. The virus isolated as the cause of the disease was determined as SARS-CoV2. A global epidemic was declared
Confict of Interest The authors declare no competing interests. Ethics Approval This study was carried out with approval of Ethical Committee of Experimental Animals of the Faculty of Medicine in Inonu University (2022/7-3). The authors have no ethical conflicts to disclose. Author Contributions Conceptualization, K.T.; methodology, K.T. software, K.T.;
References
Abdi, Jalilian, Sarbarzeh, Zjdr, Diabetes and COVID-19: A systematic review on the current evidences
Adams, Franco, Agjeb, Medicine, Reactive nitrogen species in cellular signaling
Antelmann, Helmann, Thiol-based redox switches and gene regulation
Arslan, Yaşar, Çolak, Yoloğlu, WSSPAS: an interactive web application for sample size and power analysis with R using shiny
Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients, N Engl J Med
Cecchini, Aljmh, SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression
Delgado-Roche, Fjaomr, Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection
Demirbag, Yilmaz, Erel, Gultekin, Asci et al., The relationship between potency of oxidative stress and severity of dilated cardiomyopathy, Can J Cardiol
Ekici, Temelli, Parlakpinar, Samdanci, Polat et al., Beneficial effects of aminoguanidine on radiotherapy-induced kidney and testis injury, Andrologia
Erel, A new automated colorimetric method for measuring total oxidant status, Clinical biochemistry
Erel, A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation, Clinical biochemistry
Erel, A novel automated method to measure total antioxidant response against potent free radical reactions, Clinical biochemistry
Esterbauer, Cheeseman, Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal, Methods Enzymol
Fischer, Eron, Holman, Cohen, Fang et al., Molnupiravir, an oral antiviral treatment for COVID-19
Fischer, Eron, Holman, Cohen, Fang et al., an Oral Antiviral Treatment for COVID-19, medRxiv
Focosi, Molnupiravir: From Hope to Epic Fail?, Viruses
Gordon, Tchesnokov, Schinazi, Gotte, Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template, J Biol Chem
Khoo, Fitzgerald, Fletcher, Ewings, Jaki et al., Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study, J Antimicrob Chemother
Ks, Aa, Kalala, Pm, Sabarathinam, Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases, Diabetes Metab Syndr
Lavillette, Barbouche, Yao, Boson, Cosset et al., Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV envelope
Law, Ho, Law, Cheung, Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases, World J Hepatol
Mihalopoulos, Dogra, Mohamed, Badani, Njeuf, COVID-19 and kidney disease: molecular determinants and clinical implications in renal cancer
Ntyonga-Pono, COVID-19 infection and oxidative stress: an under-explored approach for prevention and treatment
Ozdemir, Gokce, Taslidere, Tanbek, Gul et al., Does Chrysin prevent severe lung damage in Hyperoxia-Induced lung injury Model?, International immunopharmacology
Painter, Natchus, Cohen, Holman, Painter, Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19, Curr Opin Virol
Pourkarim, Pourtaghi-Anvarian, Rezaee, Molnupiravir: A new candidate for COVID-19 treatment, Pharmacol Res Perspect
Prasad, Muralidhara, Protective effects of geraniol (a monoterpene) in a diabetic neuropathy rat model: attenuation of behavioral impairments and biochemical perturbations, J Neurosci Res
Reedy, Loo, Levine, AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C, Dig Dis Sci
Schafer, Martinez, Won, Moreira, Brown et al., Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice, bioRxiv
Schieber, Nsjcb, ROS function in redox signaling and oxidative stress
Schou, Joca, Wegener, Richter, Psychiatric and neuropsychiatric sequelae of COVID-19 -A systematic review, Brain Behav Immun
Singh, Singh, Singh, Misra, Molnupiravir in COVID-19: A systematic review of literature, Diabetes Metab Syndr
Sun, Oberley, Li, A simple method for clinical assay of superoxide dismutase, Clin Chem
Tanbek, Ozerol, Bilgic, Iraz, Sahin et al., Protective effect of Nigella sativa oil against thioacetamide-induced liver injury in rats
Tanbek, Ozerol, Yilmaz, Yilmaz, Gul et al., Alpha lipoic acid decreases neuronal damage on brain tissue of STZ-induced diabetic rats, Physiol Behav
Tarnawski, Ahluwalia, Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs, World J Gastroenterol
Wen, Chen, Tang, Wang, Zhou et al., Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis, Ann Med
Yoshikawa, Yjjmaj, What is oxidative stress?
Çolak, Hjjotomc, Hayvan deneyleri: in vivo denemelerin bildirimi: ARRIVE Kılavuzu-Derleme
{ 'indexed': {'date-parts': [[2024, 9, 9]], 'date-time': '2024-09-09T15:18:27Z', 'timestamp': 1725895107781}, 'reference-count': 0, 'publisher': 'Scientific Archives LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2023, 11, 4]], 'date-time': '2023-11-04T00:00:00Z', 'timestamp': 1699056000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://www.scientificarchives.com/about-us'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Molnupiravir (MOL) is an orally absorbed prodrug of the ribonucleoside analogue ' 'N-hydroxycytidine, which has in vitro activity against several coronaviruses, including ' 'SARS-CoV-1 and 2. It remains to be seen whether long term MOL has serious side effects. The ' 'side effects of MOL, which was the first to be allowed for oral use during the pandemic ' 'process, are not yet fully known. In this study, it was aimed to investigate the the ' 'mechanisms of possible dose-dependent damage on liver, lung, heart, and kidney tissues. \n' 'Fourty male Wistar albino rats were separated into four groups as Control, MOL10, MOL100, ' 'MOL1000. For five days, MOL (10-100-1000 mg/kg/day) was administered by oral gavaj. At the ' 'end of the five days rats were sacrificed and alanine aminotransferase (ALT), aspartate ' 'aminotransferase (AST), and total bilirubin (TB) levels in serum were measured. Collected ' 'tissues (liver, lung, heart, and kidney) were evaluated to the malondialdehyde (MDA), ' 'superoxide dismutase (SOD), total antioxidant state (TAS), and total oxidant state (TOS), and ' 'oxidative stress indexes (OSI) were calculated. MOL administration showed significant ' 'improvement in liver, heart, and kidney in rats (p&lt;0.05). SOD activities which were ' 'decreased in the MOL group, while MDA level increased in the MOL groups compared to the ' 'control group in all tissue (p&lt;0.05). ALT was increased in the MOL group compared to the ' 'control group (p&lt;0.05). Increase of TOS and OSI is statistically significant, but TAS was ' 'decreased in the MOL group compared to the control group (p&lt;0.05). MOL used in virus ' 'treatment is dose-dependently effective on the oxidant/antioxidant system in tissues. For ' 'this reason, the use of antioxidants may be beneficial to reduce tissue damage that may occur ' 'in the use of MOL.</jats:p>', 'DOI': '10.33696/pharmacol.4.044', 'type': 'journal-article', 'created': {'date-parts': [[2023, 11, 4]], 'date-time': '2023-11-04T06:47:39Z', 'timestamp': 1699080459000}, 'page': '44-52', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Dose-dependent Oxidative Damage of Molnupiravir (Antiviral Drug for Treatment of COVID-19) in ' 'Lung, Liver, Heart, and Kidney Tissues in Rats', 'prefix': '10.33696', 'volume': '5', 'author': [ { 'given': 'Kevser', 'family': 'TANBEK', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Physiology, Faculty of Medicine, Inonu University, ' '44280 Malatya, Turkey,Department of Biochemistry, Faculty of ' 'Medicine, Inonu University, 44280 Malatya, Turkey'}]}, { 'given': 'Suleyman', 'family': 'SANDAL', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Physiology, Faculty of Medicine, Inonu University, ' '44280 Malatya, Turkey'}]}], 'member': '18993', 'published-online': {'date-parts': [[2023, 11, 4]]}, 'container-title': 'Archives of Pharmacology and Therapeutics', 'original-title': [], 'language': 'en', 'deposited': { 'date-parts': [[2023, 11, 4]], 'date-time': '2023-11-04T06:47:40Z', 'timestamp': 1699080460000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.scientificarchives.com/article/dose-dependent-oxidative-damage-of-molnupiravir-%28antiviral-drug-for-treatment-of-covid-19%29-in-lung-%2C-liver-%2C-heart-%2C-and-kidney-tissues-in-rats'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11, 4]]}, 'references-count': 0, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 11, 4]]}}, 'URL': 'http://dx.doi.org/10.33696/Pharmacol.4.044', 'relation': {}, 'ISSN': ['2688-9609'], 'subject': [], 'container-title-short': 'Arch Pharmacol Ther', 'published': {'date-parts': [[2023, 11, 4]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit